TORONTO, Aug. 15, 2025 /CNW/ – SpinaFX Medical Inc., (“SpinaFX”) a leading innovator in image-guided interventional spine care, is proud to announce that its flagship device, Triojection®, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). This milestone acknowledges Triojection’s potential to offer a highly
We have recently welcomed Jodi Menezes to SpinaFX as Head of Clinical Affairs. Jodi joins us from Johnson & Johnson, with a decade of experience in the MedTech industry, where she has built a strong foundation in driving business growth, operational efficiencies, and strategic market expansion. In her role as Head of Clinical Affairs at
April 10-12, 2025 SpinaFX was honored to participate in the 33rd Interdisciplinary Research Conference on Injectable Osteoarticular Biomaterials and Bone Augmentation (GRIBOI), held at the Fairmont Banff Springs Hotel in Banff, Alberta, Canada. At Booth #3, our team engaged with interventional spine and pain specialists, researchers, and industry leaders from
Banff, Alberta, Canada SpinaFX, a Canadian company focused on developing minimally invasive, image-guided treatments for back pain caused by contained herniated discs, proudly participated in the 33rd Interdisciplinary Research Conference on Injectable Osteoarticular Biomaterials and Bone Augmentation (GRIBOI 2025). Held from April 10 to 12 at the Fairmont Banff Springs
Advancing Innovative Spinal Treatment for Contained Herniated Discs [Toronto, Canada, 18th of December – 2024] – SpinaFX Medical Inc., an innovator in minimally invasive image-guided spinal care solutions, proudly announces the successful completion of its Series B funding round, raising its last tranche of CAD $5.3 million. “This investment, led by a
SIR Abstract of the Year study highlights promising treatment option for lumbar disc herniation with radiculopathy TORONTO, ONTARIO, January 17, 2023—Minimally invasive image-guided therapy company, SpinaFX Medical Inc. (SpinaFX), applauds the results of a randomized control trial conducted in Europe that demonstrated non-inferiority of intradiscal oxygen-ozone therapy to microdiscectomy for
TORONTO, Nov. 9, 2022 /PRNewswire/ – Minimally invasive image-guided treatment solution and technology company, SpinaFX Medical Inc. (SpinaFX), today announced the quality management system underlying its Triojection® system has been certified compliant with ISO 13485:2016/Medical Device Single Audit Program (MDSAP) for U.S. and Canada and EN ISO 13485:2016 for Europe.
Company’s medical advisor will present the SIR 2022 Abstract of the Year TORONTO, ONTARIO, June 10, 2022—Minimally invasive image-guided therapy company, SpinaFX Medical Inc. (SpinaFX), today announced it will exhibit at the Society of Interventional Radiology (SIR) 2022 Annual Scientific Meeting in Boston, MA, June 11-16, at booth 414. Dr.
TORONTO, ONTARIO, May 26, 2022— Minimally invasive image-guided therapy start-up, SpinaFX Medical Inc. (SpinaFX), today announced significant milestones hit since closing its $6.88M CDN Series A round in November 2021. SpinaFX has leveraged investment proceeds for patent estate expansion, product enhancements, quality management system implementation, regulatory approval pursuits and commercialization
TORONTO, ONTARIO, April 5, 2022 Minimally invasive image-guided therapy start-up, SpinaFX Medical Inc. (SpinaFX), is pleased to announce the appointment of Dr. Kieran Murphy as Chief Medical Officer and member of the Board of Directors of SpinaFX Medical. “Dr. Murphy has been a pioneer in the field of intradiscal ozone